Study on a New Induction Therapy for Leukemia

What we are studying

Studies have shown that the survival rates for patients with Very High Risk Acute Lymphoblastic Leukemia (VHR-ALL) are still poor despite treatment with the usual drugs given in higher doses, different combinations, and for different lengths of treatment. We want to find ways to improve survival rates for patients with VHR-ALL by using treatment methods and drugs that are not usual, during the post-Induction phase of therapy.

Who we are studying

  • Men and Women
  • Races:
    • White
    • African American
    • Asian
    • American Indian or Alaska Native
    • Native Hawaiian or Pacific Islander
    • Other
  • All Ethnicities
  • Ages 13+

Eligibility Criteria

  • Have Leukemia cells in your spinal fluid or brain at diagnosis
  • Leukemia has not responded quickly to Induction cancer fighting medicine (Chemotherapy)

What is involved

  • Female patients are expected to receive treatment on this study for about 2¼ years.
  • Because males receive longer Maintenance therapy - males are expected to receive treatment on this study for about 3¼ years.



Contact Information

Study Coordinator
Graham Keyes

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.